Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin with intracranial neural sensing in chronic pain
NCT06919640Phase 1Enrolling by invitation
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in chronic pain. Primary endpoint: Changes in neural functional connectivity at 90 days. Started Jun 2025; status: enrolling by invitation.
02
Drugs
psilocybin
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT06919640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919640.